Dr. Caleb J. Scheckel, D.O.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Oklahoma State University College of Osteopathic Medicine (2016)
- Years since graduation
- 10
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 821
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Medical school: Oklahoma State University College of Osteopathic Medicine
- 2016Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
OK license 7579 · MN license 65515 -
Internal Medicine Physician
AZ license 007342 · MN license 65515
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ascension St John Medical Center Tulsa, OK
- Ascension St John Jane Phillips Bartlesville, OK
- Ascension St John Broken Arrow Broken Arrow, OK
- Oklahoma State University Medical Center Tulsa, OK
- Ascension St John Sapulpa Sapulpa, OK
Medical groups
- Oklahoma Cancer Specialists and Research Institute, LLC (47 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 821
- Services billed
- 171,529
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 14,201 | 160 |
| Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 8,580 | 11 |
| Injection, granisetron, extended-release, 0.1 mg | 8,100 | 61 |
| Injection, nivolumab, 1 mg | 7,960 | 17 |
| Injection, aprepitant, 1 mg | 7,670 | 40 |
| Injection, pembrolizumab, 1 mg | 7,000 | 19 |
| Injection, paclitaxel, 1 mg | 6,208 | 24 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 5,400 | 15 |
| Injection, lanreotide, 1 mg | 2,520 | 13 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,497 | 136 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Tulsa, OK | 218 |
| Revlimid (lenalidomide) | 120 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Tulsa, OK | 92 |
| Venclexta (venetoclax) | 90 |
| Ondansetron Odt (ondansetron) Other prescribers in Tulsa, OK | 83 |
| Levofloxacin Other prescribers in Tulsa, OK | 72 |
| Dexamethasone Other prescribers in Tulsa, OK | 68 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Tulsa, OK | 66 |
| Prednisone Other prescribers in Tulsa, OK | 62 |
| Brukinsa (zanubrutinib) | 59 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 84 payments worth $107,359 in total to this clinician.
| Pfizer Inc. | $32,955 |
|---|---|
| Beone Medicines USA, Inc. | $30,010 |
| AstraZeneca Pharmaceuticals LP | $29,645 |
| E.r. Squibb & Sons, L.l.c. | $12,176 |
| Beigene USA, Inc. | $1,875 |
| Janssen Biotech, Inc. | $173 |
| Adaptive Biotechnologies Corporation | $139 |
| Adc Therapeutics America, Inc. | $108 |
| Compensation for services other than consulting (speaking, faculty) | $59,070 |
|---|---|
| Consulting Fee | $38,861 |
| Travel and Lodging | $7,057 |
| Food and Beverage | $2,371 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Beone Medicines USA, Inc. May 8, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $6,750 |
| AstraZeneca Pharmaceuticals LP Oct 6, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $6,560 |
| AstraZeneca Pharmaceuticals LP May 2, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $6,560 |
| Beone Medicines USA, Inc. Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $6,000 |
| Beone Medicines USA, Inc. Nov 11, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $6,000 |
| Pfizer Inc. Dec 31, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $5,750 |
| Pfizer Inc. May 7, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $5,745 |
| Pfizer Inc. May 22, 2025 | Consulting Fee ELREXFIO · ONCOLOGY | $5,500 |
| Pfizer Inc. Aug 19, 2025 | Compensation for services other than consulting (speaking, faculty) ADCETRIS · ONCOLOGY | $5,250 |
| AstraZeneca Pharmaceuticals LP Jan 25, 2025 | Consulting Fee | $4,920 |
All 44 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Dec 31, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $5,750 |
| Beone Medicines USA, Inc. Nov 11, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $6,000 |
| Beone Medicines USA, Inc. Nov 11, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Oklahoma City, OK · in-kind | $920 |
| AstraZeneca Pharmaceuticals LP Oct 31, 2025 | Travel and Lodging CALQUENCE · Oncology · travel to The Woodlands, TX | $85.62 |
| Beone Medicines USA, Inc. Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $6,000 |
| Beone Medicines USA, Inc. Oct 28, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Houston, TX · in-kind | $561 |
| Beone Medicines USA, Inc. Oct 28, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Houston, TX · in-kind | $473 |
| Beone Medicines USA, Inc. Oct 16, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $4,500 |
| AstraZeneca Pharmaceuticals LP Oct 6, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $6,560 |
| AstraZeneca Pharmaceuticals LP Sep 26, 2025 | Travel and Lodging CALQUENCE · Oncology · travel to The Woodlands, TX · in-kind Company’s descriptionSpeaker Expenses | $579 |
| E.r. Squibb & Sons, L.l.c. Sep 24, 2025 | Consulting Fee | $3,343 |
| Pfizer Inc. Aug 19, 2025 | Compensation for services other than consulting (speaking, faculty) ADCETRIS · ONCOLOGY | $5,250 |
| E.r. Squibb & Sons, L.l.c. Aug 18, 2025 | Consulting Fee | $955 |
| Pfizer Inc. Aug 14, 2025 | Travel and Lodging ADCETRIS · ONCOLOGY · travel to Oklahoma City, OK · in-kind | $932 |
| AstraZeneca Pharmaceuticals LP Aug 11, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $1,640 |
| AstraZeneca Pharmaceuticals LP Jul 29, 2025 | Consulting Fee CALQUENCE · Oncology | $2,460 |
| Beone Medicines USA, Inc. Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $2,250 |
| Pfizer Inc. Jun 20, 2025 | Compensation for services other than consulting (speaking, faculty) ELREXFIO · ONCOLOGY | $36.84 |
| AstraZeneca Pharmaceuticals LP Jun 17, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $1,640 |
| E.r. Squibb & Sons, L.l.c. Jun 3, 2025 | Consulting Fee | $1,433 |
| Pfizer Inc. Jun 2, 2025 | Consulting Fee ELREXFIO · ONCOLOGY | $1,540 |
| Pfizer Inc. Jun 2, 2025 | Consulting Fee ELREXFIO · ONCOLOGY | $770 |
| Pfizer Inc. May 22, 2025 | Consulting Fee ELREXFIO · ONCOLOGY | $5,500 |
| Pfizer Inc. May 22, 2025 | Compensation for services other than consulting (speaking, faculty) ADCETRIS · ONCOLOGY | $28.58 |
| Pfizer Inc. May 17, 2025 | Travel and Lodging ELREXFIO · ONCOLOGY · travel to Miami Beach, FL · in-kind | $885 |
| Pfizer Inc. May 17, 2025 | Travel and Lodging ELREXFIO · ONCOLOGY · travel to Miami Beach, FL · in-kind | $486 |
| Pfizer Inc. May 17, 2025 | Travel and Lodging ELREXFIO · ONCOLOGY · travel to Miami Beach, FL · in-kind | $480 |
| E.r. Squibb & Sons, L.l.c. May 15, 2025 | Consulting Fee | $1,194 |
| E.r. Squibb & Sons, L.l.c. May 12, 2025 | Consulting Fee | $3,820 |
| Beone Medicines USA, Inc. May 8, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $6,750 |
| Beone Medicines USA, Inc. May 8, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to San Diego, CA | $110 |
| Pfizer Inc. May 7, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $5,745 |
| AstraZeneca Pharmaceuticals LP May 2, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $6,560 |
| Pfizer Inc. Apr 26, 2025 | Travel and Lodging ADCETRIS · ONCOLOGY · travel to Dallas, TX · in-kind | $468 |
| Pfizer Inc. Apr 26, 2025 | Travel and Lodging ADCETRIS · ONCOLOGY · travel to Dallas, TX · in-kind | $327 |
| AstraZeneca Pharmaceuticals LP Apr 24, 2025 | Travel and Lodging CALQUENCE · Oncology · travel to Oklahoma City, OK · in-kind Company’s descriptionSpeaker Expenses | $752 |
| Beone Medicines USA, Inc. Mar 21, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $1,875 |
| AstraZeneca Pharmaceuticals LP Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $250 |
| Pfizer Inc. Mar 17, 2025 | Compensation for services other than consulting (speaking, faculty) ADCETRIS · ONCOLOGY | $4,275 |
| AstraZeneca Pharmaceuticals LP Mar 13, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $3,280 |
| AstraZeneca Pharmaceuticals LP Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $300 |
| Beigene USA, Inc. Feb 4, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $1,875 |
| E.r. Squibb & Sons, L.l.c. Jan 29, 2025 | Consulting Fee | $1,433 |
| AstraZeneca Pharmaceuticals LP Jan 25, 2025 | Consulting Fee | $4,920 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $7,503 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
AbbVie Inc. · Recruiting · NCT06428019 - A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refract…
Celgene Corporation - A study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.